Logo image of ALCAR.PA

CARMAT (ALCAR.PA) Stock Price, Quote, News and Overview

EPA:ALCAR - Euronext Paris - Matif - FR0010907956 - Common Stock - Currency: EUR

0.799  -0.01 (-1.28%)

ALCAR.PA Quote, Performance and Key Statistics

CARMAT

EPA:ALCAR (5/8/2025, 7:00:00 PM)

0.799

-0.01 (-1.28%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
Statistics
52 Week High4.39
52 Week Low0.69
Market Cap47.00M
Shares58.82M
Float47.81M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)09-10 2025-09-10
IPO07-07 2010-07-07


ALCAR.PA short term performance overview.The bars show the price performance of ALCAR.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

ALCAR.PA long term performance overview.The bars show the price performance of ALCAR.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ALCAR.PA is 0.799 EUR. In the past month the price decreased by -1.36%. In the past year, price decreased by -80.98%.

CARMAT / ALCAR Daily stock chart

ALCAR.PA Competitors/Peers

The largest stocks on the EU markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABL.DE ABBOTT LABORATORIES 28.33 206.87B
IUI1.DE INTUITIVE SURGICAL INC 71.49 172.45B
BSX.DE BOSTON SCIENTIFIC CORP 39.08 137.55B
2M6.DE MEDTRONIC PLC 15.89 95.77B
SHL.DE SIEMENS HEALTHINEERS AG 20.73 52.61B
BOX.DE BECTON DICKINSON AND CO 12.06 42.93B
EWL.DE EDWARDS LIFESCIENCES CORP 29.37 39.54B
DC4.DE DEXCOM INC 51.94 29.53B
1PHIA.MI KONINKLIJKE PHILIPS NV 16.09 21.02B
PHIA.AS KONINKLIJKE PHILIPS NV 15.87 20.29B
PHI1.DE KONINKLIJKE PHILIPS NV 15.48 20.23B
BIM.PA BIOMERIEUX 30.05 13.73B

About ALCAR.PA

Company Profile

ALCAR logo image Carmat SA is a medtech that designs, manufactures and markets the Aeson artificial heart. The company is headquartered in Velizy-Villacoublay, Ile-De-France. The company went IPO on 2010-07-07. The firm is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. The company specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The firm formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.

Company Info

CARMAT

36, avenue de l'Europe

Velizy-Villacoublay ILE-DE-FRANCE FR

Employees: 162

ALCAR Company Website

ALCAR Investor Relations

Phone: 33139456450

CARMAT / ALCAR.PA FAQ

What is the stock price of CARMAT today?

The current stock price of ALCAR.PA is 0.799 EUR. The price decreased by -1.28% in the last trading session.


What is the ticker symbol for CARMAT stock?

The exchange symbol of CARMAT is ALCAR and it is listed on the Euronext Paris - Matif exchange.


On which exchange is ALCAR.PA stock listed?

ALCAR.PA stock is listed on the Euronext Paris - Matif exchange.


What is the price forecast or stock price prediction for CARMAT stock?

14 analysts have analysed ALCAR.PA and the average price target is 3.71 EUR. This implies a price increase of 363.83% is expected in the next year compared to the current price of 0.799. Check the CARMAT stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CARMAT worth?

CARMAT (ALCAR.PA) has a market capitalization of 47.00M EUR. This makes ALCAR.PA a Nano Cap stock.


How many employees does CARMAT have?

CARMAT (ALCAR.PA) currently has 162 employees.


What are the support and resistance levels for CARMAT (ALCAR.PA) stock?

CARMAT (ALCAR.PA) has a support level at 0.79 and a resistance level at 0.83. Check the full technical report for a detailed analysis of ALCAR.PA support and resistance levels.


Is CARMAT (ALCAR.PA) expected to grow?

The Revenue of CARMAT (ALCAR.PA) is expected to grow by 19.57% in the next year. Check the estimates tab for more information on the ALCAR.PA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CARMAT (ALCAR.PA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CARMAT (ALCAR.PA) stock pay dividends?

ALCAR.PA does not pay a dividend.


When does CARMAT (ALCAR.PA) report earnings?

CARMAT (ALCAR.PA) will report earnings on 2025-09-10.


What is the Price/Earnings (PE) ratio of CARMAT (ALCAR.PA)?

CARMAT (ALCAR.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.76).


ALCAR.PA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ALCAR.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ALCAR.PA. ALCAR.PA has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALCAR.PA Financial Highlights

Over the last trailing twelve months ALCAR.PA reported a non-GAAP Earnings per Share(EPS) of -1.76. The EPS increased by 21.62% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -98.49%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%36.26%
Sales Q2Q%494.03%
EPS 1Y (TTM)21.62%
Revenue 1Y (TTM)517.77%

ALCAR.PA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to ALCAR.PA. The Buy consensus is the average rating of analysts ratings from 14 analysts.

For the next year, analysts expect an EPS growth of 42.6% and a revenue growth 19.57% for ALCAR.PA


Ownership
Inst Owners0.69%
Ins Owners11.03%
Short Float %N/A
Short RatioN/A
Analysts
Analysts84.29
Price Target3.71 (364.33%)
EPS Next Y42.6%
Revenue Next Year19.57%